Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The trial that the investigators are proposing is a pilot study to determine the effect of the new WHO-yaws eradication strategy in Lihir Island (population 18,000), Papua New Guinea. New treatment policies were developed by WHO in 2012 to replace those of the 1950s. The recommended practice is to offer an initial MDA with azithromycin to the entire population, followed by resurveys every 6 months to detect and treat remaining cases.We will use serology surveys, clinical surveys and ulcer aetiology studies to measure the effect of mass azithromycin treatment on the community burden of yaws infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lihir Medical Centre
• Collaborators: Barcelona Institute for Global Health; National Department of Health of Papua New Guinea; University of Washington; World Health Organization
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Whole resident population for MDA and clinical surveys, and children 5-15 years in sentinel sites for cross-sectional serological surveys.

Exclusion Criteria:

• Children younger than 2 months and pregnant women;

• Known allergy to macrolide antibiotics;

• Refusal of individual or guardian (for individual inclusion).